Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry’s push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows.
If you are not happy with the results below please do another search
50 search results for:
To fast-track the time to market and gain a competitive edge, pharmaceutical development companies are increasingly implementing single-use technologies (SUT).
AstraZeneca shared positive results from the company’s TOPAZ-1 Phase III trial on Imfinzi (durvalumab) in increasing the chances for survival in advanced biliary tract cancer patients when combined with standard-of-care chemotherapy regimens.
The U.S. Food and Drug Administration greenlit Xipere, the first suprachoroidal injectable medicine for macular edema associated with uveitis, co-developed by Clearside Biomedical and Bausch & Lomb.
Dupixent (dupilumab) scored the blockbuster medicine’s second study win in a week after Regeneron Pharmaceuticals and Sanofi revealed positive results from the second Phase III trial for the treatment of eosinophilic esophagitis (EoE).
Merck on Oct. 25 revealed positive results from two Phase III trials on a potential treatment for adults with HIV-1 infection and are virologically suppressed on different antiretroviral regimens (ART).
Moderna Inc. said on Oct. 25 the company’s Covid-19 vaccine generated a strong immune response in children aged 6 to 11 years and plans to submit the data to global regulators soon.
The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030.
Novartis said on Oct. 25 the company’s canakinumab drug failed in another clinical trial, missing targets to improve overall survival rates for lung cancer patients and prevent the progression-free survival of people with the condition.
Roche is launching a new genomic profiling kit that lets cancer researchers explore tumors without having to send tissue samples to centralized laboratories, the Swiss drugmaker said on Oct. 25.